Bold claim: a single gene family could redefine how we predict and treat liver cancer. And this is where the conversation gets really important: FAM72 may be a key to both diagnosing hepatocellular carcinoma (HCC) and forecasting patient outcomes more accurately than many existing models.
A recent bioinformatics study shines a spotlight on the FAM72 gene family as a powerful prognostic marker in HCC. Researchers found that high expression of FAM72A–D correlates with more advanced disease and poorer survival. By analyzing data from The Cancer Genome Atlas (TCGA) and validating the findings across multiple external cohorts (ICGC and three GEO datasets), they showed all four FAM72 genes are markedly upregulated in tumor tissue compared with normal liver. Importantly, higher FAM72 levels align with higher TNM stage, worse histological grade, and diminished overall survival. Diagnostic performance was impressive, with areas under the receiver operating characteristic curve (AUC) ranging from 0.88 to 0.94 when distinguishing tumor from normal tissue.
Two-gene signature outperforms many models
Digging deeper, the team developed a concise FAM72-based risk score. Although FAM72A–D mutations occurred relatively frequently (up to 17%) and associated with poorer survival, a minimalist two-gene signature—FAM72A and FAM72D—effectively separated patients into high- and low-risk groups across five independent cohorts. This two-gene model maintained time-dependent AUCs generally above 0.63 and achieved a concordance index higher than ten previously published multi-gene HCC prognostic models, all while using far fewer genes.
Biological context and implications
Single-cell RNA sequencing revealed FAM72B–D enrichment in proliferating T cells, while FAM72A appeared in myeloid and endothelial cells as well. This pattern suggests roles for FAM72 not only within tumor cells but also in shaping the immune microenvironment. High FAM72 expression and elevated risk scores also linked to altered immune infiltration, including shifts in T-cell subsets and higher expression of immune checkpoints like PDCD1, CD274, CTLA4, HAVCR2, ICOS, and TIGIT. These insights hint at potential implications for immunotherapy strategies.
Mechanistic insights and drivers
Copy-number variation emerged as the primary driver of FAM72 overexpression, rather than changes in promoter methylation. Pathway analyses associated the high-risk FAM72 signature with cell-cycle control, DNA repair processes, and MYC-related programs, aligning with roles in tumor proliferation and genomic instability.
Bottom line
The authors propose that FAM72A–D hold promise as diagnostic and prognostic biomarkers in HCC. The streamlined two-gene FAM72 risk score could aid patient risk stratification and inform future immunotherapy decision-making.
Reference
Kong W et al. Systematic analysis of the expression profiles and prognostic values of the FAM72 family in liver cancer. Biochem Biophys Rep. 2025;DOI:10.1016/j.bbrep.2025.102358.
Author:
All content is provided under the Creative Commons Attribution-Non Commercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/).
